Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
The SUSTAIN-6 trial , published in the New England Journal of Medicine in 2016, found that participants taking semaglutide had a higher rate of diabetic retinopathy complications compared to placebo (3.0% versus 1.8%)
M., DeSilva D., Pickart L., Aust S
April 13-18, 2024
Clinical Trial Evidence: Landmark cardiovascular outcome trials (CVOTs) like the SELECT trial (for semaglutide) have shown a significant reduction in major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death
As these sources decline, reduced glucose and insulin levels stimulates free fatty acids mobilisation from adipose tissue
Li C, Xiong Y, Fu Z, Ji Y, Yan J, Kong Y
